[
    [
        {
            "time": "2021-04-19",
            "original_text": "恒瑞医药2020年营收同比增长19.09%",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "营收",
                    "同比增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药2020年营收同比增长19.09%",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-04-19",
            "original_text": "恒瑞医药发布2020年报：研发投入大手笔；抗肿瘤产品营收增逾44%",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "年报",
                    "研发投入",
                    "抗肿瘤",
                    "营收增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药发布2020年报：研发投入大手笔；抗肿瘤产品营收增逾44%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-04-19",
            "original_text": "恒瑞医药2020年业绩稳健增长 研发投入近50亿元",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "业绩增长",
                    "研发投入"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药2020年业绩稳健增长 研发投入近50亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-04-19",
            "original_text": "恒瑞医药(600276.SH)一季度净利润升13.77%至14.97亿元",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "一季度",
                    "净利润",
                    "增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药(600276.SH)一季度净利润升13.77%至14.97亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-19",
            "original_text": "恒瑞医药(600276.SH)2020年度净利润升18.78%至63.28亿元拟10送2派2元",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "年度",
                    "净利润",
                    "分红"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药(600276.SH)2020年度净利润升18.78%至63.28亿元拟10送2派2元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-04-19",
            "original_text": "恒瑞医药：一季度剔除股权激励费用影响净利润升24.24%研发费用大增62.26%",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "一季度",
                    "净利润",
                    "研发费用",
                    "增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药：一季度剔除股权激励费用影响净利润升24.24%研发费用大增62.26%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-19",
            "original_text": "北向资金爆买逾160亿元，新能源汽车概念股获大幅加仓",
            "features": {
                "keywords": [
                    "北向资金",
                    "新能源汽车",
                    "加仓"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "新能源汽车"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "北向资金爆买逾160亿元，新能源汽车概念股获大幅加仓",
                "Correlation": 2,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-19",
            "original_text": "机构抱团股大反攻！聪明资金埋伏一季报个股名单曝光",
            "features": {
                "keywords": [
                    "机构抱团",
                    "一季报",
                    "个股名单"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "机构抱团股大反攻！聪明资金埋伏一季报个股名单曝光",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-19",
            "original_text": "东吴证券 - 医药生物行业：第五批带量采购对恒瑞医药影响有限，仍坚定看好【行业研究】",
            "features": {
                "keywords": [
                    "东吴证券",
                    "医药生物",
                    "带量采购",
                    "恒瑞医药"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "东吴证券 - 医药生物行业：第五批带量采购对恒瑞医药影响有限，仍坚定看好【行业研究】",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]